APA

Dieci M. V., Prat A., Tagliafico E., Paré L., Ficarra G., Bisagni G., Piacentini F., Generali D. G., Conte P. & Guarneri V. (20171222). Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Dieci M V, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali D G, Conte P and Guarneri V. 20171222. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Dieci M. V., Prat A., Tagliafico E., Paré L., Ficarra G., Bisagni G., Piacentini F., Generali D. G., Conte P. and Guarneri V. (20171222). Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Dieci M V, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali D G, Conte P and Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. : Annals of oncology : official journal of the European Society for Medical Oncology. 20171222.